JP2006514099A - 組織化前の三環系インテグラーゼインヒビター化合物 - Google Patents
組織化前の三環系インテグラーゼインヒビター化合物 Download PDFInfo
- Publication number
- JP2006514099A JP2006514099A JP2005501423A JP2005501423A JP2006514099A JP 2006514099 A JP2006514099 A JP 2006514099A JP 2005501423 A JP2005501423 A JP 2005501423A JP 2005501423 A JP2005501423 A JP 2005501423A JP 2006514099 A JP2006514099 A JP 2006514099A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- substituted
- phosphonate
- alkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*(C(*)=C(C)C(*)(*)C1NC(*=*=*2)=C2C(*)=C11)C1=O Chemical compound C*(C(*)=C(C)C(*)(*)C1NC(*=*=*2)=C2C(*)=C11)C1=O 0.000 description 30
- FCMLWBBLOASUSO-UHFFFAOYSA-N CC(C)(C)OC(N(CCN1)CC1=O)=O Chemical compound CC(C)(C)OC(N(CCN1)CC1=O)=O FCMLWBBLOASUSO-UHFFFAOYSA-N 0.000 description 1
- XOYDXQIVFSUKDK-UHFFFAOYSA-N CC(C)(C)OC(N(CCN1Cc(cc2)ccc2F)CC1=O)=O Chemical compound CC(C)(C)OC(N(CCN1Cc(cc2)ccc2F)CC1=O)=O XOYDXQIVFSUKDK-UHFFFAOYSA-N 0.000 description 1
- WLTLMLLLFUJCOQ-UHFFFAOYSA-N CC(C)OC(c(nccc1)c1C(N(CCN1Cc(cc2)ccc2F)CC1=O)=O)=O Chemical compound CC(C)OC(c(nccc1)c1C(N(CCN1Cc(cc2)ccc2F)CC1=O)=O)=O WLTLMLLLFUJCOQ-UHFFFAOYSA-N 0.000 description 1
- JJHMFZQIZDCYJV-UHFFFAOYSA-N CC(CC1)CN(CC2C=CC(F)=CC2)C1=O Chemical compound CC(CC1)CN(CC2C=CC(F)=CC2)C1=O JJHMFZQIZDCYJV-UHFFFAOYSA-N 0.000 description 1
- XMWINMVFKPHMJB-UHFFFAOYSA-N CC1=CCCC=C1 Chemical compound CC1=CCCC=C1 XMWINMVFKPHMJB-UHFFFAOYSA-N 0.000 description 1
- NJFLZLAEALJDFE-UHFFFAOYSA-N CCC(c(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)=O Chemical compound CCC(c(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)=O NJFLZLAEALJDFE-UHFFFAOYSA-N 0.000 description 1
- NWNJUOSUYIMJMN-UHFFFAOYSA-N CCCCNC(Oc(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)=O Chemical compound CCCCNC(Oc(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)=O NWNJUOSUYIMJMN-UHFFFAOYSA-N 0.000 description 1
- OBCBDHFCSIEZFZ-UHFFFAOYSA-N CCOC(CNC(N(CC(OCC)=O)C(Oc(c(CN1Cc(cc2)ccc2F)c2C1=O)c(cccn1)c1c2O)=O)=O)=O Chemical compound CCOC(CNC(N(CC(OCC)=O)C(Oc(c(CN1Cc(cc2)ccc2F)c2C1=O)c(cccn1)c1c2O)=O)=O)=O OBCBDHFCSIEZFZ-UHFFFAOYSA-N 0.000 description 1
- LRZPBJNCADMGPE-UHFFFAOYSA-N CCOC(CNC(N(CC(OCC)=O)C(Oc(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)=O)=O)=O Chemical compound CCOC(CNC(N(CC(OCC)=O)C(Oc(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)=O)=O)=O LRZPBJNCADMGPE-UHFFFAOYSA-N 0.000 description 1
- FSNCRSIVDAWNRJ-UHFFFAOYSA-N CCOC(c1ccccc1-c(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)=O Chemical compound CCOC(c1ccccc1-c(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)=O FSNCRSIVDAWNRJ-UHFFFAOYSA-N 0.000 description 1
- QZKVVOXAEBCLPZ-UHFFFAOYSA-N CCOC(c1ccccc1B(O)O)=O Chemical compound CCOC(c1ccccc1B(O)O)=O QZKVVOXAEBCLPZ-UHFFFAOYSA-N 0.000 description 1
- YOWPRXGSHUETEH-UHFFFAOYSA-N CCOP(CN(CC1)CCN1C(Oc(c(CN1Cc(cc2)ccc2F)c2C1=O)c(cccn1)c1c2O)=O)(OCC)=O Chemical compound CCOP(CN(CC1)CCN1C(Oc(c(CN1Cc(cc2)ccc2F)c2C1=O)c(cccn1)c1c2O)=O)(OCC)=O YOWPRXGSHUETEH-UHFFFAOYSA-N 0.000 description 1
- HULJRNLUJZHSAT-UHFFFAOYSA-N CCOP(CN(CC1)CCN1C(Oc(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)=O)(OCC)=O Chemical compound CCOP(CN(CC1)CCN1C(Oc(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)=O)(OCC)=O HULJRNLUJZHSAT-UHFFFAOYSA-N 0.000 description 1
- BJLCQRNXUYMQGX-UHFFFAOYSA-N CCOP(COc(c(C(N1Cc(cc2)ccc2F)=O)c2C1=O)c(cccn1)c1c2OCOC)(OCC)=O Chemical compound CCOP(COc(c(C(N1Cc(cc2)ccc2F)=O)c2C1=O)c(cccn1)c1c2OCOC)(OCC)=O BJLCQRNXUYMQGX-UHFFFAOYSA-N 0.000 description 1
- WRIZLDGIENMLKJ-UHFFFAOYSA-N CN(C)C(Oc(c1c(c(OC(c2ccccc2)c2ccccc2)c2C(N3Cc(cc4)ccc4F)=O)nccc1)c2C3=O)=O Chemical compound CN(C)C(Oc(c1c(c(OC(c2ccccc2)c2ccccc2)c2C(N3Cc(cc4)ccc4F)=O)nccc1)c2C3=O)=O WRIZLDGIENMLKJ-UHFFFAOYSA-N 0.000 description 1
- XMVLPQQBYBKRSC-UHFFFAOYSA-N CN(CC1)CCN1C(c(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2O)=O Chemical compound CN(CC1)CCN1C(c(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2O)=O XMVLPQQBYBKRSC-UHFFFAOYSA-N 0.000 description 1
- LZLCRLFICGGDOL-UHFFFAOYSA-N CN(CC1)CCN1C(c(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)=O Chemical compound CN(CC1)CCN1C(c(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)=O LZLCRLFICGGDOL-UHFFFAOYSA-N 0.000 description 1
- CDRSBPYJKRZQAY-UHFFFAOYSA-N COC(N1CCOCC1)=O Chemical compound COC(N1CCOCC1)=O CDRSBPYJKRZQAY-UHFFFAOYSA-N 0.000 description 1
- NBHQVSARENATMP-UHFFFAOYSA-N COC(c(c1c(c2c3cccn2)O)c3OC)N(Cc(cc2)ccc2F)C1=O Chemical compound COC(c(c1c(c2c3cccn2)O)c3OC)N(Cc(cc2)ccc2F)C1=O NBHQVSARENATMP-UHFFFAOYSA-N 0.000 description 1
- YLGIBCYHQZTFQL-UHFFFAOYSA-N COC(c1c(C(OC)=O)nccc1)=O Chemical compound COC(c1c(C(OC)=O)nccc1)=O YLGIBCYHQZTFQL-UHFFFAOYSA-N 0.000 description 1
- GNPAJMHWDXTGEU-UHFFFAOYSA-N COCc(c(CN1Cc(cc2)ccc2F)c2C1=O)c(cccn1)c1c2O Chemical compound COCc(c(CN1Cc(cc2)ccc2F)c2C1=O)c(cccn1)c1c2O GNPAJMHWDXTGEU-UHFFFAOYSA-N 0.000 description 1
- BVCPOBBMOIJWQM-UHFFFAOYSA-N COS(N1CCOCC1)(=O)=O Chemical compound COS(N1CCOCC1)(=O)=O BVCPOBBMOIJWQM-UHFFFAOYSA-N 0.000 description 1
- OMYDADTZOQJGJY-UHFFFAOYSA-N COc(c1c2nccc1)c(C(N(Cc(cc1)ccc1F)C1=O)O)c1c2O Chemical compound COc(c1c2nccc1)c(C(N(Cc(cc1)ccc1F)C1=O)O)c1c2O OMYDADTZOQJGJY-UHFFFAOYSA-N 0.000 description 1
- MOFOVVZFIXSIBO-UHFFFAOYSA-N COc(c1c2nccc1)c(CNCc1ccc(C(F)(F)F)cc1)c(C=O)c2O Chemical compound COc(c1c2nccc1)c(CNCc1ccc(C(F)(F)F)cc1)c(C=O)c2O MOFOVVZFIXSIBO-UHFFFAOYSA-N 0.000 description 1
- ALCKIYMYIPZUSA-UHFFFAOYSA-N COc1ccc(COc(c(nccc2)c2c(OC)c2CCC3Cc4ccc(C(C5)C5F)cc4)c2C3=O)cc1 Chemical compound COc1ccc(COc(c(nccc2)c2c(OC)c2CCC3Cc4ccc(C(C5)C5F)cc4)c2C3=O)cc1 ALCKIYMYIPZUSA-UHFFFAOYSA-N 0.000 description 1
- UHGMNYPRMIAFOS-UHFFFAOYSA-N C[BrH]Cc(cc1)ccc1[FH+] Chemical compound C[BrH]Cc(cc1)ccc1[FH+] UHGMNYPRMIAFOS-UHFFFAOYSA-N 0.000 description 1
- FLRUNCJXOVYWDH-UHFFFAOYSA-N Fc1ccc(CCBr)cc1 Chemical compound Fc1ccc(CCBr)cc1 FLRUNCJXOVYWDH-UHFFFAOYSA-N 0.000 description 1
- CEEWLJFUTGENPZ-UHFFFAOYSA-N O=C(N1CCOCC1)Oc(c1c(c(OC(c2ccccc2)c2ccccc2)c2C(N3Cc(cc4)ccc4F)=O)nccc1)c2C3=O Chemical compound O=C(N1CCOCC1)Oc(c1c(c(OC(c2ccccc2)c2ccccc2)c2C(N3Cc(cc4)ccc4F)=O)nccc1)c2C3=O CEEWLJFUTGENPZ-UHFFFAOYSA-N 0.000 description 1
- NEJCULBWOMKEQW-UHFFFAOYSA-N O=C(c(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)N1CCOCC1 Chemical compound O=C(c(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)N1CCOCC1 NEJCULBWOMKEQW-UHFFFAOYSA-N 0.000 description 1
- YGRYIEXQGCBECY-UHFFFAOYSA-N O=C(c(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)NCc1ncccc1 Chemical compound O=C(c(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)NCc1ncccc1 YGRYIEXQGCBECY-UHFFFAOYSA-N 0.000 description 1
- JXUZFCKBLOLVNA-UHFFFAOYSA-N O=C(c1c(c2c3cccn2)OC(c2ccccc2)c2ccccc2)N(Cc(cc2)ccc2F)Cc1c3-c1cccnc1F Chemical compound O=C(c1c(c2c3cccn2)OC(c2ccccc2)c2ccccc2)N(Cc(cc2)ccc2F)Cc1c3-c1cccnc1F JXUZFCKBLOLVNA-UHFFFAOYSA-N 0.000 description 1
- RCWYUURMVCVMDC-UHFFFAOYSA-N O=C(c1c2OC(c3ccccc3)c3ccccc3)N(Cc(cc3)ccc3F)Cc1c(C[Tl])c1c2nccc1 Chemical compound O=C(c1c2OC(c3ccccc3)c3ccccc3)N(Cc(cc3)ccc3F)Cc1c(C[Tl])c1c2nccc1 RCWYUURMVCVMDC-UHFFFAOYSA-N 0.000 description 1
- YUHZIUAREWNXJT-UHFFFAOYSA-N OB(c1cccnc1F)O Chemical compound OB(c1cccnc1F)O YUHZIUAREWNXJT-UHFFFAOYSA-N 0.000 description 1
- SXKNKZFUVSCCQQ-UHFFFAOYSA-N OC(c(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)=O Chemical compound OC(c(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)=O SXKNKZFUVSCCQQ-UHFFFAOYSA-N 0.000 description 1
- HWDKPMIPFNVPRN-UHFFFAOYSA-N OC(c1c2cccn1)=C(C(N(Cc(cc1)ccc1F)CC1)=O)N1C2=O Chemical compound OC(c1c2cccn1)=C(C(N(Cc(cc1)ccc1F)CC1)=O)N1C2=O HWDKPMIPFNVPRN-UHFFFAOYSA-N 0.000 description 1
- XTPMFKUKVFNGHE-UHFFFAOYSA-N OCc(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2O Chemical compound OCc(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2O XTPMFKUKVFNGHE-UHFFFAOYSA-N 0.000 description 1
- OUVKQCAXDVOIIT-UHFFFAOYSA-N Oc(c(nccc1)c1c(C(NCc1ncccc1)=O)c1CN2Cc(cc3)ccc3F)c1C2=O Chemical compound Oc(c(nccc1)c1c(C(NCc1ncccc1)=O)c1CN2Cc(cc3)ccc3F)c1C2=O OUVKQCAXDVOIIT-UHFFFAOYSA-N 0.000 description 1
- BKQRDTTVKLDXEW-UHFFFAOYSA-N Oc(c1c(c(OC(c2ccccc2)c2ccccc2)c2C(N3Cc(cc4)ccc4F)=O)nccc1)c2C3=O Chemical compound Oc(c1c(c(OC(c2ccccc2)c2ccccc2)c2C(N3Cc(cc4)ccc4F)=O)nccc1)c2C3=O BKQRDTTVKLDXEW-UHFFFAOYSA-N 0.000 description 1
- CXEDAXOASGQHFN-UHFFFAOYSA-N Oc(c1c2CN(Cc(cc3)ccc3F)C1=O)c1ncccc1c2-c1cccnc1F Chemical compound Oc(c1c2CN(Cc(cc3)ccc3F)C1=O)c1ncccc1c2-c1cccnc1F CXEDAXOASGQHFN-UHFFFAOYSA-N 0.000 description 1
- VLNUQIHFXPXQNT-UHFFFAOYSA-N [O-][N+](CCc(cc1)ccc1F)(Cc1c2c(O)c3ncccc3c1O)C2=O Chemical compound [O-][N+](CCc(cc1)ccc1F)(Cc1c2c(O)c3ncccc3c1O)C2=O VLNUQIHFXPXQNT-UHFFFAOYSA-N 0.000 description 1
- VSFMEENYJBQXBL-UHFFFAOYSA-N [O-][N+](c(cc1)ccc1OC(Oc(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)=O)=O Chemical compound [O-][N+](c(cc1)ccc1OC(Oc(c1c2nccc1)c(CN(Cc(cc1)ccc1F)C1=O)c1c2OC(c1ccccc1)c1ccccc1)=O)=O VSFMEENYJBQXBL-UHFFFAOYSA-N 0.000 description 1
- KRCDZVCKWRELBZ-UHFFFAOYSA-N [O-][NH+](CCC=O)NCCc(cc1)ccc1F Chemical compound [O-][NH+](CCC=O)NCCc(cc1)ccc1F KRCDZVCKWRELBZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41896302P | 2002-10-16 | 2002-10-16 | |
| US47878303P | 2003-06-16 | 2003-06-16 | |
| PCT/US2003/032666 WO2004035576A2 (en) | 2002-10-16 | 2003-10-16 | Pre-organized tricyclic integrase inhibitor compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006514099A true JP2006514099A (ja) | 2006-04-27 |
| JP2006514099A5 JP2006514099A5 (https=) | 2007-01-25 |
Family
ID=32110203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005501423A Pending JP2006514099A (ja) | 2002-10-16 | 2003-10-16 | 組織化前の三環系インテグラーゼインヒビター化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20040157804A1 (https=) |
| EP (1) | EP1558613A2 (https=) |
| JP (1) | JP2006514099A (https=) |
| KR (1) | KR20050087787A (https=) |
| CN (1) | CN100374438C (https=) |
| AP (1) | AP1858A (https=) |
| AU (2) | AU2003301439A1 (https=) |
| BR (1) | BR0315405A (https=) |
| CA (1) | CA2501881A1 (https=) |
| EA (1) | EA011399B1 (https=) |
| HR (1) | HRP20050431A2 (https=) |
| IS (1) | IS7845A (https=) |
| MX (1) | MXPA05003950A (https=) |
| NO (1) | NO20052378L (https=) |
| NZ (1) | NZ539264A (https=) |
| OA (1) | OA13079A (https=) |
| PL (1) | PL377966A1 (https=) |
| UA (1) | UA79830C2 (https=) |
| WO (2) | WO2004035577A2 (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007532665A (ja) * | 2004-04-14 | 2007-11-15 | ギリアード サイエンシーズ, インコーポレイテッド | Hivインテグラーゼ阻害剤化合物のホスホネート類似物 |
| JP2009537546A (ja) * | 2006-05-16 | 2009-10-29 | ギリアード サイエンシーズ, インコーポレイテッド | インテグラーゼ阻害剤 |
| JP2015510927A (ja) * | 2012-03-28 | 2015-04-13 | キュン ドン ファーマ. カンパニー. リミテッド. | ソリフェナシン又はその塩の製造方法及びここに用いられる新規な中間体 |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1183025T3 (da) * | 1999-05-19 | 2009-05-04 | Painceptor Pharma Corp | Hæmmere af proton-styrede kationskanaler og deres anvendelse til behandling af iskæmiske lidelser |
| AU2004234087A1 (en) * | 2003-04-28 | 2004-11-11 | Tibotec Pharmaceuticals Ltd. | HIV integrase inhibitors |
| CA2537325A1 (en) * | 2003-09-19 | 2005-03-31 | Gilead Sciences, Inc. | Aza-quinolinol phosphonate integrase inhibitor compounds |
| CN101415487A (zh) * | 2003-12-08 | 2009-04-22 | 纽约州立大学研究基金会 | 传感器应用中的位点选择性标记和模板分子印记聚合物 |
| EP1694686A1 (en) | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
| EP1706728A4 (en) * | 2004-01-07 | 2008-03-12 | Univ New York State Res Found | PROTEIN IMPREGNATED POLYMERS WITH INTEGRATED TRANSMISSION SITES |
| US7538112B2 (en) * | 2004-05-07 | 2009-05-26 | Merck & Co., Inc. | HIV integrase inhibitors |
| US7476666B2 (en) | 2004-06-09 | 2009-01-13 | Merck & Co., Inc. | HIV integrase inhibitors |
| WO2006023931A2 (en) | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| US7745459B2 (en) | 2004-09-21 | 2010-06-29 | Japan Tobacco Inc. | Quinolizinone compound and use thereof as HIV integrase inhibitor |
| EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| AR057023A1 (es) * | 2005-05-16 | 2007-11-14 | Gilead Sciences Inc | Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa |
| WO2006122403A1 (en) | 2005-05-19 | 2006-11-23 | Merck Frosst Canada Ltd. | Quinoline derivatives as ep4 antagonists |
| EP1906971A2 (en) * | 2005-07-27 | 2008-04-09 | Gilead Sciences, Inc. | Antiviral compounds |
| EP1909578A4 (en) * | 2005-08-04 | 2010-07-14 | Glaxosmithkline Llc | INHIBITORS OF HIV INTEGRASE |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| WO2007076005A2 (en) * | 2005-12-21 | 2007-07-05 | Gilead Sciences, Inc. | Processes and intermediates useful for preparing integrase inhibitor compounds |
| US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| EP1976517A1 (en) | 2005-12-30 | 2008-10-08 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| US20090291921A1 (en) * | 2007-11-20 | 2009-11-26 | Gilead Sciences, Inc. | Integrase inhibitors |
| ES2572631T3 (es) | 2008-01-25 | 2016-06-01 | Chimerix, Inc. | Métodos de tratamiento de infecciones virales |
| WO2010011814A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| RU2530899C2 (ru) * | 2008-07-28 | 2014-10-20 | Селлсьютикс Корпорейшн | Противомалярийные соединения |
| CN102245572B (zh) | 2008-12-11 | 2015-03-25 | 盐野义制药株式会社 | 氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体 |
| KR101733625B1 (ko) | 2008-12-11 | 2017-05-10 | 시오노기세야쿠 가부시키가이샤 | 카르바모일피리돈 hiv 인테그라제 억제제 및 중간체의 합성 |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| EP2270021A1 (en) * | 2009-06-18 | 2011-01-05 | Centre National de la Recherche Scientifique | Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability |
| WO2011011483A1 (en) * | 2009-07-22 | 2011-01-27 | Glaxosmithkline Llc | Chemical compounds |
| ES2446720T3 (es) | 2009-10-13 | 2014-03-10 | Elanco Animal Health Ireland Limited | Inhibidores de la integrasa macrocíclica |
| US8283366B2 (en) | 2010-01-22 | 2012-10-09 | Ambrilia Biopharma, Inc. | Derivatives of pyridoxine for inhibiting HIV integrase |
| JP5745869B2 (ja) * | 2010-01-22 | 2015-07-08 | 富山化学工業株式会社 | アルアルキル基を有する複素環化合物 |
| US9006218B2 (en) | 2010-02-12 | 2015-04-14 | Chimerix Inc. | Nucleoside phosphonate salts |
| TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Viiv醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
| TWI503323B (zh) | 2010-03-29 | 2015-10-11 | Oncotherapy Science Inc | 三環化合物以及含此化合物之pbk抑制劑 |
| WO2011121105A1 (en) | 2010-04-02 | 2011-10-06 | Tibotec Pharmaceuticals | Macrocyclic integrase inhibitors |
| CA2830027C (en) | 2011-03-31 | 2016-04-26 | Pfizer Inc. | Novel bicyclic pyridinones |
| ES3018133T3 (en) | 2011-11-30 | 2025-05-14 | Univ Emory | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | N4-ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| MX368391B (es) | 2015-02-03 | 2019-09-30 | Pfizer | Ciclopropabenzofuranil-piridopirazindionas novedosas. |
| CN104803905B (zh) * | 2015-04-17 | 2017-10-10 | 复旦大学 | 一种合成异吲哚啉‑1‑酮衍生物的方法 |
| WO2017133517A1 (zh) * | 2016-02-03 | 2017-08-10 | 四川海思科制药有限公司 | 一种磷酰胺衍生物及制备方法和用途 |
| CN109305990B (zh) * | 2017-07-28 | 2021-02-26 | 四川海思科制药有限公司 | 一种磷酸衍生物及制备方法和用途 |
| CN109305989B (zh) * | 2017-07-28 | 2021-02-26 | 四川海思科制药有限公司 | 一种磷酰胺衍生物及制备方法和用途 |
| PT3706762T (pt) | 2017-12-07 | 2024-12-05 | Univ Emory | N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002030931A2 (en) * | 2000-10-12 | 2002-04-18 | Merck & Co., Inc. | Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| WO2002030426A1 (en) * | 2000-10-12 | 2002-04-18 | Merck & Co., Inc. | Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH385846A (de) * | 1960-03-31 | 1964-12-31 | Geigy Ag J R | Verfahren zur Herstellung von neuen 7-Acyl-8-hydroxy-chinolinen und ihre Verwendung als Fungizide und Bakterizide im Pflanzen- und Materialschutz |
| US4816570A (en) * | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) * | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| EP0533833B1 (en) | 1990-06-13 | 1995-12-20 | GLAZIER, Arnold | Phosphorous produgs |
| EP0481214B1 (en) * | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
| ES2104862T3 (es) * | 1991-02-07 | 1997-10-16 | Roussel Uclaf | Derivados biciclicos nitrogenados, su procedimiento de preparacion, sus productos intermedios obtenidos, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen. |
| EP0520573A1 (en) * | 1991-06-27 | 1992-12-30 | Glaxo Inc. | Cyclic imide derivatives |
| US5639881A (en) * | 1991-11-08 | 1997-06-17 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis and elucidation of pyrimido (4,5-Q) quinazoline derivatives |
| TW304945B (https=) * | 1992-06-27 | 1997-05-11 | Hoechst Ag | |
| US5798340A (en) * | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5538988A (en) * | 1994-04-26 | 1996-07-23 | Martinez; Gregory R. | Benzocycloalkylazolethione derivatives |
| US5854275A (en) * | 1996-05-16 | 1998-12-29 | Pfizer Inc. | Cyclic imide derivatives |
| US6310211B1 (en) * | 1996-09-10 | 2001-10-30 | Pharmacia & Upjohn Company | 8-hydroxy-7-substituted quinolines as anti-viral agents |
| AU8689298A (en) * | 1997-08-05 | 1999-03-01 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
| US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| AU4225499A (en) | 1998-06-03 | 1999-12-20 | Merck & Co., Inc. | Hiv integrase inhibitors |
| CA2329134A1 (en) | 1998-06-03 | 1999-12-09 | David L. Clark | Hiv integrase inhibitors |
| EP1086102A1 (en) * | 1998-06-10 | 2001-03-28 | Arena Pharmaceuticals, Inc. | Acetylcholine enhancers |
| US6187907B1 (en) * | 1998-08-31 | 2001-02-13 | James Chen | Triple helix coil template having a biologically active ligand |
| AU3118200A (en) | 1998-12-14 | 2000-07-03 | Merck & Co., Inc. | Hiv integrase inhibitors |
| PL348596A1 (en) | 1998-12-25 | 2002-06-03 | Shionogi & Co | Aromatic heterocycle compounds having hiv integrase inhibiting activities |
| TR200202129T2 (tr) | 1999-06-02 | 2003-03-21 | Shionogi & Co., Ltd. | Yeni ikameli propenon türevlerinin hazırlanması için prosesler. |
| AU5880600A (en) | 1999-06-25 | 2001-01-31 | Merck & Co., Inc. | 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof |
| US6245806B1 (en) | 1999-08-03 | 2001-06-12 | Merck & Co., Inc. | HIV integrase inhibitors |
| AU8009900A (en) * | 1999-10-13 | 2001-04-23 | Merck & Co., Inc. | Hiv integrase inhibitors |
| ATE345129T1 (de) | 2000-10-12 | 2006-12-15 | Merck & Co Inc | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
| WO2002036734A2 (en) | 2000-10-12 | 2002-05-10 | Merck & Co., Inc. | Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors |
| WO2002030970A2 (en) * | 2000-10-13 | 2002-04-18 | Bayer Aktiengesellschaft | Human histone deacetylase gene |
| US6518767B1 (en) * | 2000-10-19 | 2003-02-11 | Schweitzer Engineering Laboratories, Inc. | Line differential protection system for a power transmission line |
| WO2005117904A2 (en) * | 2004-04-14 | 2005-12-15 | Gilead Sciences, Inc. | Phosphonate analogs of hiv integrase inhibitor compounds |
-
2003
- 2003-10-15 WO PCT/US2003/032866 patent/WO2004035577A2/en not_active Ceased
- 2003-10-15 US US10/687,374 patent/US20040157804A1/en not_active Abandoned
- 2003-10-15 AU AU2003301439A patent/AU2003301439A1/en not_active Abandoned
- 2003-10-16 JP JP2005501423A patent/JP2006514099A/ja active Pending
- 2003-10-16 EP EP03809030A patent/EP1558613A2/en not_active Withdrawn
- 2003-10-16 PL PL377966A patent/PL377966A1/pl not_active Application Discontinuation
- 2003-10-16 WO PCT/US2003/032666 patent/WO2004035576A2/en not_active Ceased
- 2003-10-16 CN CNB2003801061816A patent/CN100374438C/zh not_active Expired - Fee Related
- 2003-10-16 BR BR0315405-0A patent/BR0315405A/pt not_active IP Right Cessation
- 2003-10-16 NZ NZ539264A patent/NZ539264A/en not_active IP Right Cessation
- 2003-10-16 KR KR1020057006668A patent/KR20050087787A/ko not_active Ceased
- 2003-10-16 MX MXPA05003950A patent/MXPA05003950A/es active IP Right Grant
- 2003-10-16 CA CA002501881A patent/CA2501881A1/en not_active Abandoned
- 2003-10-16 UA UAA200504480A patent/UA79830C2/uk unknown
- 2003-10-16 AP AP2005003279A patent/AP1858A/xx active
- 2003-10-16 HR HR20050431A patent/HRP20050431A2/hr not_active Application Discontinuation
- 2003-10-16 US US10/687,373 patent/US7253180B2/en not_active Expired - Fee Related
- 2003-10-16 OA OA1200500108A patent/OA13079A/en unknown
- 2003-10-16 AU AU2003301306A patent/AU2003301306A1/en not_active Abandoned
- 2003-10-16 EA EA200500660A patent/EA011399B1/ru not_active IP Right Cessation
-
2005
- 2005-05-13 IS IS7845A patent/IS7845A/is unknown
- 2005-05-13 NO NO20052378A patent/NO20052378L/no not_active Application Discontinuation
-
2007
- 2007-05-25 US US11/807,303 patent/US20090029939A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002030931A2 (en) * | 2000-10-12 | 2002-04-18 | Merck & Co., Inc. | Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| WO2002030426A1 (en) * | 2000-10-12 | 2002-04-18 | Merck & Co., Inc. | Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors |
| WO2002030930A2 (en) * | 2000-10-12 | 2002-04-18 | Merck & Co., Inc. | Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
Non-Patent Citations (3)
| Title |
|---|
| JPN6010013756, Journal of Organic Chemistry, 1998, Vol.63, No.22, p.7680−7686 * |
| JPN6010013759, Heterocycles, 1998, Vol.48, No.5, p.853−860 * |
| JPN6010013761, Synthesis, 1996, No.10, p.1180−1182 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007532665A (ja) * | 2004-04-14 | 2007-11-15 | ギリアード サイエンシーズ, インコーポレイテッド | Hivインテグラーゼ阻害剤化合物のホスホネート類似物 |
| JP2009537546A (ja) * | 2006-05-16 | 2009-10-29 | ギリアード サイエンシーズ, インコーポレイテッド | インテグラーゼ阻害剤 |
| JP2015510927A (ja) * | 2012-03-28 | 2015-04-13 | キュン ドン ファーマ. カンパニー. リミテッド. | ソリフェナシン又はその塩の製造方法及びここに用いられる新規な中間体 |
Also Published As
| Publication number | Publication date |
|---|---|
| NO20052378L (no) | 2005-07-18 |
| AU2003301306A1 (en) | 2004-05-04 |
| US7253180B2 (en) | 2007-08-07 |
| EP1558613A2 (en) | 2005-08-03 |
| US20040157804A1 (en) | 2004-08-12 |
| AU2003301439A1 (en) | 2004-05-04 |
| MXPA05003950A (es) | 2005-06-17 |
| AP1858A (en) | 2008-06-30 |
| AU2003301439A8 (en) | 2004-05-04 |
| US20040167124A1 (en) | 2004-08-26 |
| CN100374438C (zh) | 2008-03-12 |
| CA2501881A1 (en) | 2004-04-29 |
| WO2004035577A3 (en) | 2004-07-29 |
| CN1726212A (zh) | 2006-01-25 |
| EA011399B1 (ru) | 2009-02-27 |
| HRP20050431A2 (en) | 2005-10-31 |
| IS7845A (is) | 2005-05-13 |
| UA79830C2 (en) | 2007-07-25 |
| KR20050087787A (ko) | 2005-08-31 |
| WO2004035576A2 (en) | 2004-04-29 |
| AP2005003279A0 (en) | 2005-06-30 |
| EA200500660A1 (ru) | 2005-10-27 |
| PL377966A1 (pl) | 2006-02-20 |
| NZ539264A (en) | 2007-08-31 |
| OA13079A (en) | 2006-11-10 |
| US20090029939A1 (en) | 2009-01-29 |
| WO2004035576A3 (en) | 2004-06-24 |
| WO2004035577A2 (en) | 2004-04-29 |
| BR0315405A (pt) | 2005-08-09 |
| NO20052378D0 (no) | 2005-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7253180B2 (en) | Pre-organized tricyclic integrase inhibitor compounds | |
| JP2006514099A5 (https=) | ||
| US7462721B2 (en) | Aza-quinolinol phosphonate integrase inhibitor compounds | |
| JP6460991B2 (ja) | 抗菌剤として使用するための三環式ジャイレース阻害剤 | |
| US20070072831A1 (en) | Integrase inhibitor compounds | |
| US8008287B2 (en) | Integrase inhibitors | |
| AU2005249363A1 (en) | Phosphonate analogs of HIV integrase inhibitor compounds | |
| WO2009067541A2 (en) | Integrase inhibitors | |
| US20050282839A1 (en) | Pyrimidyl phosphonate antiviral compounds and methods of use | |
| US20060217410A1 (en) | Pre-organized tricyclic integrase inhibitor compounds | |
| US20080153783A1 (en) | Pyrimidyl Phosphonate Antiviral Compounds and Methods of Use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061013 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061013 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20061204 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100310 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100318 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100907 |